Abstract

BackgroundNaturally derived compounds play a tremendous role as a drug as well as lead structure for the development of APIs. Therefore, isolation and characterization of compounds from nature are needed to alleviate life-threatening diseases. A. precatorius L. belongs to the family Leguminosae and is valued for its medicinal properties. Therefore, in this study, efforts are being made to isolate bioactive entity based on HPTLC-DPPH bioautography from APHA extract. Among all the separated compounds on TLC plate, the one (APSP-3) at Rf = 0.67 showed significant antioxidant activity, and hence, APSP-3 was further subjected to isolation, purification, and structural characterization using diverse analytical modus operandi such as 1D and 2D NMR, FTIR, HPLC–MS/MS, and elemental analysis. In addition, antioxidant and cytotoxicity evaluation of APHA extract and APSP-3 was pursued by standard DPPH and colorimetric MTT assays, respectively.ResultsAntioxidative isolated compound APSP-3 was scrutinized based on HPTLC-DPPH bioautography. The APSP-3 was found novel and spectroscopic data revealed the plausible structure; 7-hydroxy-3,5-dimethoxy-2-(4-((3,4,5-trihydroxy-6-(hydroxymethyl) tetrahydro-2H-pyran-2-yl)oxy) phenyl)-4H-chromen-4-one. Moreover, APSP-3 ascribed higher free radical scavenging activity with IC50 = 38.70 ± 3.5 µg/mL than standard ascorbic acid (75.19 ± 1.5 µg/mL). Cytotoxicity evaluation of APHA extract exhibited IC50 value 122.09 µg/mL for HepG2, 122.61 µg/mL for MCF-7, and 48.08 µg/mL for HCT116 cell lines, while APSP-3 displayed IC50 values 96.75 for HepG2, 61.67 for MCF-7, and 47.61 µg/mL for HCT116 cell lines.ConclusionsIn a nutshell, HPTLC-directed bioautography leads to the capturing of new flavonoid entity having antioxidant potency from APHA extract. The IC50 values obtained from cytotoxicity establish a dose–response relationship helping to determine the concentration at which a substance begins to exhibit toxic effects. This fundamental information is crucial for establishing safe dosage level in medical and pharmaceutical applications. Further, research engrossed in assessing other bioactivities involving in silico and in vivo studies obliged to offer a promising and secure portrayal for clinical implications.Graphical abstract

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.